Features

Top 20 Pharma Report

By Gil Y. Roth, Editor | July 18, 2012

Our annual look at the 20 biggest players in the Pharmaceutical marketplace

It was quite a strange year for our top pharmas. A top 10 company spun off its innovative pharma unit, the biggest acquisition came from a company at the bottom of our list (Gilead's $11 billion purchase of Pharmasset and its hepatitis C pipeline), and the biggest launch came from a company that's not even in the Top 20: Vertex, which posted almost $1 billion in revenues in seven months for HCV treatment Incivek.

The ranks were relatively stable, with minor shifts based on acquisition integrations. More often,  exchange rate fluctuations tweaked the results a bit, boosting companies that would otherwise look anemic or worse. The euro and krone both rose 5%, the British pound was up 4%, the yen was up 9%, and the Swiss franc blew up 18%.

For USD-reporting companies, total revenues rose 6% to $301.5 billion. The days of double-digits are long gone . . .

—Gil Y. Roth
Editor


Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth

Photo courtesy of Eli Lilly & Co.

Top 20 Pharmaceutical Companies 
based on 2011 pharma revenues

1

Pfizer 

$57,747

2

Novartis

$47,935

3

Sanofi

$42,779

4

Merck

$41,289

5

GlaxoSmithKline 

$35,594

6

AstraZeneca

$32,981

7

Johnson & Johnson

$24,368

8

Eli Lilly & Co.

$22,608

9

Abbott Laboratories

$22,435

10

Bristol-Myers Squibb

$21,244

11

Takeda Pharma

$17,257

12

Teva

$16,689

13

Boehringer-Ingelheim

$14,058

14

Bayer Schering

$13,853

15

Astellas

$12,311

16

Daiichi-Sankyo

$11,338

17

Otsuka Pharmaceutical

$9,935

18

Gilead Sciences

$8,102

19

EISAI 

$7,710

20

Mylan

$6,106


Note: In all Top Company profiles, dollar amounts are in millions.

blog comments powered by Disqus